Lexicon Genetics Incorporated to Present at the Biotechnology Industry Organization (BIO) 2007 International Convention
Published: May 07, 2007
THE WOODLANDS, Texas, May 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the BIO 2007 International Convention at the Boston Convention Center, Boston, Massachusetts on Wednesday, May 9, 2007 at 9:15 a.m. Eastern Time. Dr. Sands will participate in the Business Forum under the Drug Discovery category and provide an overview of Lexicon's clinical and preclinical development programs, collaborations and corporate objectives for 2007.
Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon and Takeda Pharmaceutical Company Limited. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's plans regarding regulatory filings and clinical development programs for LX6171 and LX1031 and the potential therapeutic and commercial potential of LX6171 and LX1031 and other potential drug candidates in Lexicon's preclinical pipeline. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX6171 and LX1031 and preclinical development of other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.
CONTACT: Bobbie Faulkner, Investor Relations of Lexicon Pharmaceuticals,Inc., +1-281-863-3503, or firstname.lastname@example.org
Web site: http://www.lexpharma.com/